Sk Biopharmaceuticals Co Ltd Cash Flow Quality Index
Sk Biopharmaceuticals Co Ltd cash flow quality index. Sk Biopharmaceuticals Co Ltd (326030) has a Cash Flow Quality Index of 0.17x as of March 2026. Operating cash flow of ₩17.92 Billion is below net income of ₩105.16 Billion, suggesting accrual-heavy earnings not yet converted to cash. Explore cash flow to debt ratio of Sk Biopharmaceuticals Co Ltd to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Sk Biopharmaceuticals Co Ltd (2021–2025)
Cash flow quality index of Sk Biopharmaceuticals Co Ltd from 2021 to 2025. Historical Cash Flow Quality Index for Sk Biopharmaceuticals Co Ltd across 3 annual periods. Values consistently above 1.0x indicate high-quality earnings. See Sk Biopharmaceuticals Co Ltd balance sheet independence to measure how much of total assets are equity-financed.
Sk Biopharmaceuticals Co Ltd Cash Flow Quality Index by Year (2021–2025)
Sk Biopharmaceuticals Co Ltd cash flow quality index by year from 2021 to 2025. Year-by-year earnings quality comparison for Sk Biopharmaceuticals Co Ltd. For the full cash flow conversion analysis, see cash flow conversion of Sk Biopharmaceuticals Co Ltd.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.66x | ₩176.33 Billion | ₩266.95 Billion | ▲ +67.6% |
| 2024 | 0.39x | ₩94.90 Billion | ₩240.74 Billion | ▲ +127.5% |
| 2021 | -1.43x | ₩-92.87 Billion | ₩64.85 Billion | — |